What changed: HPV-positive oropharyngeal cancer
Every dated change on the records linked to HPV-positive oropharyngeal cancer, newest first: approvals and regulatory steps on its medicines, trials that reported, guideline versions, milestones, and when this page itself was checked. Dates come from the records; none is inferred. Orientation, not medical advice.
Trial result6Milestone8This record1
September 2026 · 1
2025 · 2
- 2025Trial resultNRG-HN002 & NRG-HN005 (HPV+ de-escalation)NRG-HN002 & NRG-HN005 (HPV+ de-escalation) reported
HN005: de-escalated arms had worse PFS; control 2-year PFS 98%.
- 2025MilestoneNRG-HN002 & NRG-HN005 (HPV+ de-escalation)NRG-HN005 closed: de-escalated chemoradiation arms worse
A milestone in how this cancer is treated.
2022 · 2
2021 · 1
2020 · 1
2019 · 4
- 2019Trial resultDe-ESCALaTE HPVDe-ESCALaTE HPV reported
Severe toxicity similar; 2-year overall survival 97.
- 2019Trial resultKEYNOTE-048KEYNOTE-048 reported
OS 14.
- 2019Trial resultRTOG 1016RTOG 1016 reported
5-year overall survival 84.
- 2019MilestoneRTOG 1016RTOG 1016 and De-ESCALaTE: cetuximab inferior to cisplatin
A milestone in how this cancer is treated.